The GPM6B Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma line. This product comprises a heterogeneous pool of cells with targeted disruption of the GPM6B gene, providing a powerful loss-of-function model without clonal selection. The polyclonal format preserves the genetic diversity of the edited population, enabling studies that average out clonal variations while maintaining the overall knockout effect. This polyclonal knockout model is designed to facilitate robust and reproducible investigations into GPM6B function in a colorectal epithelial context.
The HT29 host cell line was originally established from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female. HT29 cells exhibit characteristics of colon epithelial cells and are widely used as a model for intestinal epithelial physiology and colorectal cancer. Under standard culture conditions, HT29 cells grow as an undifferentiated monolayer, but upon reaching confluence or treatment with inducers such as sodium butyrate, they can differentiate into absorptive enterocytes. This dual capacity makes HT29 an adaptable platform for studying epithelial differentiation and tumorigenesis, providing a physiologically relevant background for interrogating gene function in colorectal cancer.
GPM6B encodes a transmembrane glycoprotein belonging to the proteolipid protein family, originally characterized for its role in neuronal differentiation, neurite outgrowth, and synaptic function. In epithelial cells, GPM6B is implicated in the regulation of cell adhesion and migration, potentially through modulation of integrin-mediated adhesion and cytoskeletal dynamics. Mechanistically, GPM6B is positioned within a signaling network involving upstream regulators such as TCF/LEF transcription factors, TGF-beta, SMAD2/3, miR-124, and NEUROG2, and downstream targets including integrin alpha6/beta4, FAK, AKT, ERK1/2, RhoA, and CDH1 (E-cadherin). The protein interacts with amyloid precursor protein (APP), BACE1, GPM6A, and FLOT2. Consequently, disruption of GPM6B is expected to perturb TGF-beta signaling via TGFBR1, SMAD2, and SMAD3, as well as Wnt/beta-catenin signaling through CTNNB1 and TCF4, and Hippo pathway effectors YAP and TAZ. These interconnected pathways collectively influence epithelial-mesenchymal transition (EMT), adhesion, and migratory behavior.
In the HT29 colorectal adenocarcinoma context, knockout of GPM6B provides a physiologically relevant model to dissect its contributions to tumor cell adhesion, migration, and EMT. Given that HT29 cells retain epithelial characteristics and the capacity for differentiation, the loss of GPM6B may reveal its role in maintaining epithelial integrity or facilitating metastatic transition. This knockout model allows researchers to interrogate how GPM6B governs the balance between adhesive and migratory phenotypes by altering downstream signaling through integrin-FAK-AKT and RhoA pathways, and by modulating E-cadherin expression. Such investigations are particularly pertinent to understanding colorectal cancer progression, where EMT is a key driver of invasion and metastasis.
This polyclonal knockout cell population is ideally suited for a wide range of downstream applications. Researchers can employ western blotting and RT-qPCR to assess changes in key signaling proteins and gene expression, combined with Transwell migration/invasion assays and cell adhesion assays to directly evaluate phenotypic outcomes. Immunofluorescence staining for E-cadherin and F-actin can visualize alterations in cell-cell junctions and the cytoskeleton, while phospho-signaling analysis or RNA-seq can provide comprehensive mechanistic insights. Colony formation assays enable assessment of tumorigenic potential. These tools make the product valuable for investigating GPM6B??s role in colorectal cancer metastasis, studying EMT regulation, screening for pathway modulators, and validating GPM6B as a potential drug target. For further technical information, performance data, or assistance with experimental design, please contact Ascent Research.
